Understanding the prognosis and biomarkers of infective endocarditis
Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR): a National Multi-center, Retrospective-prospective, Cohort Study Initiated by the Investigators
This study is trying to learn more about how infective endocarditis progresses and what factors affect it by looking at patients and their biomarkers to improve diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT05965362 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a clinical cohort of patients with infective endocarditis to observe the natural prognosis and influencing factors during the disease's progression and regression. Utilizing multi-omics technology, the study seeks to uncover the prognostic value of various biomarkers associated with the condition. The findings are expected to provide new insights into the pathogenesis, clinical diagnosis, and treatment strategies for infective endocarditis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with clinically confirmed infective endocarditis.
Not a fit: Patients who refuse to sign the informed consent form or have serious systemic diseases that prevent them from tolerating biological sample acquisition may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and targeted treatment options for patients with infective endocarditis.
How similar studies have performed: While the approach of using multi-omics technology in this context is relatively novel, similar studies have shown promise in understanding other infectious diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinically confirmed infective endocarditis Exclusion Criteria: * Patients refuse to sign informed consent form * Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Where this trial is running
Xi'an, Shaanxi
- First Affiliated Hospital of Xian Jiantong University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Principal investigator: Yang Yan — First Affiliated Hospital Xi'an Jiaotong University
- Study coordinator: Guoliang Li
- Email: liguoliang_med@163.com
- Phone: +8613759982523
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.